Читать книгу Blood and Marrow Transplantation Long Term Management - Группа авторов - Страница 3

1 Chapter 2Table 2.1 Transplant Registries Collecting Data on HCT Survivors

2 Chapter 3Table 3.1 Different models of long‐term transplant clinicsTable 3.2 Significant aspects to consider when building up a long‐term follow...

3 Chapter 4Table 4.1 Telehealth modalities that can apply to Long Term Follow Up (LTFU) ...Table 4.2 Safeguarding medical information and photos in telehealthTable 4.3 Benefits and challenges of the telemedicine LTFU model for HCT surv...

4 Chapter 5Table 5.1 Elements of a survivorship care plan for patients treated with hema...Table 5.2 Check‐list of recommendations for counseling of the long‐term survi...Table 5.3 Summary of recommendations for screening and prevention of late com...

5 Chapter 6Table 6.1 Non‐relapse late and very late effects after allogeneic HCT

6 Chapter 7Table 7.1 Common Late Effects and Complications after Autologous Hematopoieti...

7 Chapter 8Table 8.1 LTFU recommendations for survivors

8 Chapter 10Table 10.1 Summary recommendations for screening and prevention of late compl...Table 10.2 Screening recommendations for subsequent malignancies in survivors...

9 Chapter 13Table 13.1 Preventive options of infections in long‐term survivors after allo...Table 13.2 Preventive options of infections in long‐term survivors after auto...

10 Chapter 14Table 14.1 Risk factors for progression to lower respiratory tract diseaseTable 14.2 Infection Control measures to reduce risk of CRV infection

11 Chapter 15Table 15.1 Classification of patient/donor depending on the HBV markersTable 15.2 Recommended measures in HCT with patients/donors with HBV infectio...Table 15.3 Possible results of the HCV screening before HCTTable 15.4 Recommended AVT against HCV depending on the viral genotypeTable 15.5 Recommended measures in HCT when patient or donor are infected by ...Table 15.6 More frequently used antiviral drugs and combinationsTable 15.7 Effect of anti‐HIV agents on HSCT drugs metabolization

12 Chapter 16Table 16.1 Approaches proposed to identify associated predictive biomarkers o...Table 16.2 Specific criteria for cGVHD from the 2014 Pathology Working GroupTable 16.3 Criteria for the diagnosis of cGVHD skin: categorization of diagno...

13 Chapter 17Table 17.1 Types of ocular complications after HSCT; screening; prevention an...Table 17.2 Treatment for ocular GVHD

14 Chapter 18Table 18.1 Oral complications of HCT

15 Chapter 19Table 19.1 Thyroid manifestations in stem cell transplant recipients, with re...

16 Chapter 20Table 20.1 When to refer to a Gynecology or Urology clinicianTable 20.2 Hormone and contraceptive options at the time of transplant

17 Chapter 21Table 21.1 When to refer to a Gynecology or Urology clinicianTable 21.2 Hormone and contraceptive options at the time of transplant

18 Chapter 24Table 24.1 Diagnostic criteria of BOS following HSCTTable 24.2 Comparison between bronchiolitis obliterans syndrome and cryptogen...

19 Chapter 26Table 26.1 Dyslipidemia ScreeningTable 26.2 Screening for HypertensionTable 26.3 Screening for diabetesTable 26.4 Screening for endocrinopathiesTable 26.5 Screening for metabolic syndrome /obesity

20 Chapter 27Table 27.1 GI side effects of common transplant conditioning medications [2,7...Table 27.2 Organ staging of acute graft versus host disease [33]Table 27.3 Freiburg criteria for macroscopic diagnosis of aGVHD [42]Table 27.4 Adapted Lerner histologic grading scale for aGVHD [50, 51]Table 27.5 Diagnostic cGVHD GI‐related organ symptoms, adapted [32]Table 27.6 NIH scoring of gastrointestinal chronic GVHD, adapted [32]

21 Chapter 28Table 28.1 Indicators of liver diseaseTable 28.2 Interpretation of HBV serologyTable 28.3 Late hepatic complications following hematopoietic stem cell transpl...

22 Chapter 29Table 29.1 Risk factors for AKI post HSCTTable 29.2 Risk factors for CKD post HSCTTable 29.3 Thrombotic microangiopathy post‐hematopoietic stem cell transplant...

23 Chapter 30Table 30.1 Screening Recommendations: Low Bone‐Mineral DensityTable 30.2 Bisphosphonate Prevention and Treatment Studies: Osteoporosis

24 Chapter 31Table 31.1 Cytotoxic and immunosuppressive agents associated with neurotoxici...Table 31.2 Cerebrovascular complications of hematopoietic stem cell transplan...Table 31.3 Immune‐mediated central and peripheral nervous system complication...Table 31.4 CNS secondary malignancies among HCT recipients in published studi...

25 Chapter 32Table 32.1 Neurocognitive Dysfunction in Special Populations

26 Chapter 33Table 33.1 Describe the most common tools assessing depression, anxiety, dist...

27 Chapter 34Table 34.1 ICD‐10 Criteria for Cancer‐Related FatigueTable 34.2 Risk factors and potential etiologies for fatigue in HSCT survivor...Table 34.3 Interventions for Fatigue Management in Cancer and HSCT SurvivorsTable 34.4 Fatigue Management Recommendations for Transplant Survivors

28 Chapter 35Table 35.1 Social Issues Associated with HCT

29 Chapter 36Table 36.1 PRO Instruments for Adult HSCT SurvivorsTable 36.2 PRO Instruments for Pediatric and AYA HSCT SurvivorsTable 36.3 Implementation Considerations for Patient‐Reported Outcome Measure...Table 36.4 Online Patient ResourcesTable 36.5 Interventions to address common issues that impair HRQL in cancer ...

30 Chapter 37Table 37.1 Comparative side effects of calcineurin inhibitors

31 Chapter 41Table 41.1 Selected examples of different CAM use in HCT literature in the la...

32 Chapter 45Table 45.1 Caregivers of long‐term survivors’ tasks and concerns

33 Appendix 1Appendix A. GVHD Prophylactic TherapyAppendix B. GVHD Treatment Therapy